Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Gibbs

Showing results (351-360 of 393) with videos related to

Pageof 40
Sort By:
Science Translational Medicine|October 27, 2017
Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patientsEvangelos D Michelakis, Vikram Gurtu, Linda Webster, et al.
Nature|March 10, 2001
A high-resolution map of human chromosome 12K T Montgomery, E Lee, A Miller, et al.
The New England Journal of Medicine|March 6, 2023
Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial HypertensionMarius M Hoeper, David B Badesch, H Ardeschir Ghofrani, et al.
Human Mutation|September 8, 2011
Molecular genetic characterization of SMAD signaling molecules in pulmonary arterial hypertensionMd Talat Nasim, Takeshi Ogo, Mohammad Ahmed, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|December 7, 2024
Efficacy and safety of sotatercept across ranges of cardiac index in patients with pulmonary arterial hypertension: A pooled analysis of PULSAR and STELLARMardi Gomberg-Maitland, David B Badesch, J Simon R Gibbs, et al.
Circulation|November 25, 2016
Plasma Metabolomics Implicates Modified Transfer RNAs and Altered Bioenergetics in the Outcomes of Pulmonary Arterial HypertensionChristopher J Rhodes, Pavandeep Ghataorhe, John Wharton, et al.
The New England Journal of Medicine|September 30, 2025
Sotatercept for Pulmonary Arterial Hypertension within the First Year after DiagnosisVallerie V McLaughlin, Marius M Hoeper, David B Badesch, et al.
The European Respiratory Journal|January 30, 2025
Efficacy and safety of the activin signalling inhibitor, sotatercept, in a pooled analysis of PULSAR and STELLAR studiesMarius M Hoeper, Mardi Gomberg-Maitland, David B Badesch, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|February 14, 2017
Survival in portopulmonary hypertension: Outcomes of the United Kingdom National Pulmonary Arterial Hypertension RegistrySasiharan Sithamparanathan, Arun Nair, Logan Thirugnanasothy, et al.
Plos One|July 3, 2014
Risk factors for death in 632 patients with sickle cell disease in the United States and United KingdomMark T Gladwin, Robyn J Barst, J Simon R Gibbs, et al.
Pageof 40

Showing results (351-360 of 393) with videos related to

Sort By:
Pageof 40
Science Translational Medicine|October 27, 2017
Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patientsEvangelos D Michelakis, Vikram Gurtu, Linda Webster, et al.
Nature|March 10, 2001
A high-resolution map of human chromosome 12K T Montgomery, E Lee, A Miller, et al.
The New England Journal of Medicine|March 6, 2023
Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial HypertensionMarius M Hoeper, David B Badesch, H Ardeschir Ghofrani, et al.
Human Mutation|September 8, 2011
Molecular genetic characterization of SMAD signaling molecules in pulmonary arterial hypertensionMd Talat Nasim, Takeshi Ogo, Mohammad Ahmed, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|December 7, 2024
Efficacy and safety of sotatercept across ranges of cardiac index in patients with pulmonary arterial hypertension: A pooled analysis of PULSAR and STELLARMardi Gomberg-Maitland, David B Badesch, J Simon R Gibbs, et al.
Circulation|November 25, 2016
Plasma Metabolomics Implicates Modified Transfer RNAs and Altered Bioenergetics in the Outcomes of Pulmonary Arterial HypertensionChristopher J Rhodes, Pavandeep Ghataorhe, John Wharton, et al.
The New England Journal of Medicine|September 30, 2025
Sotatercept for Pulmonary Arterial Hypertension within the First Year after DiagnosisVallerie V McLaughlin, Marius M Hoeper, David B Badesch, et al.
The European Respiratory Journal|January 30, 2025
Efficacy and safety of the activin signalling inhibitor, sotatercept, in a pooled analysis of PULSAR and STELLAR studiesMarius M Hoeper, Mardi Gomberg-Maitland, David B Badesch, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|February 14, 2017
Survival in portopulmonary hypertension: Outcomes of the United Kingdom National Pulmonary Arterial Hypertension RegistrySasiharan Sithamparanathan, Arun Nair, Logan Thirugnanasothy, et al.
Plos One|July 3, 2014
Risk factors for death in 632 patients with sickle cell disease in the United States and United KingdomMark T Gladwin, Robyn J Barst, J Simon R Gibbs, et al.
Pageof 40